 Predictive Oncology Inc. NASDAQ:POAI said it has further strengthened its offerings for pharmaceutical and biotech customers through several key developments. The company said the first was its Good Manufacturing Practices GMP lab, which opens the opportunity to help clients move from pre-clinical drug development to the investigational new drug IND qualification, including Phase 1 clinical trials. 